Charles River beats earnings, offers cautious 2026 outlook as shares tumble
Contract research organization reports $376M in impairments as biopharma demand shows early signs of stabilization
Charles River Laboratories International reported fourth-quarter earnings that exceeded analyst expectations, but a cautious outlook for 2026 and substantial impairment charges sent shares tumbling as investors question the pace of recovery in the contract research sector.
The Wilmington, Massachusetts-based company posted adjusted earnings per share of $2.39 for the quarter ended December 31, 2025, beating analyst estimates of approximately $2.34 to $2.35. Revenue reached $994.2 million, modestly ahead of the $990.8 million consensus, though this represents a 0.8% decline from the same period a year earlier. Despite the earnings beat, the stock has plummeted roughly 30% from its January 13 high of $228.88 to approximately $158 to $161, with technical indicators showing the shares recently traded in oversold territory.
Under the surface, the company recorded significant non-cash impairment charges totaling $376 million during the quarter, including $211 million related to intangible assets and $165 million for goodwill. These charges resulted in a GAAP loss per share of $5.62, reflecting challenges in the Biologics Solutions reporting unit and Cell Solutions business segments. The impairments weighed on profitability metrics even as adjusted results demonstrated underlying operational strength.
Chief Executive James C. Foster sought to reassure investors about the company's positioning, noting that the Discovery and Safety Assessment (DSA) segment—which constitutes a critical portion of Charles River's business—is showing signs of stabilization. "DSA net bookings improved in Q4 2025, indicating stabilization in the biopharmaceutical demand environment," Foster stated, pointing to a book-to-bill ratio of approximately 1.1 times during the period.
Looking ahead to 2026, management provided guidance that reflects cautious optimism amid an uncertain demand environment. The company anticipates reported revenue will be at least flat to up 1.5% compared to 2025, with organic revenue expected to range from a 1% decline to flat year-over-year. Management projects a return to organic revenue growth in the second half of 2026, driven by robust booking trends in the DSA segment and anticipated contributions from recent acquisitions.
The 2026 guidance incorporates several moving parts, including an expected 100 to 150 basis point benefit from foreign currency translation and more than $100 million in incremental cost savings aimed at offsetting inflationary pressures and supporting non-GAAP operating margins. The company also noted that two planned acquisitions—K.F. (Cambodia) Ltd. and PathoQuest SAS—are expected to contribute approximately $0.25 to non-GAAP earnings per share and $15 million to $20 million in revenue, respectively, during 2026.
Analysts have maintained a generally bullish stance on Charles River Laboratories despite the near-term headwinds. The consensus rating remains a "Moderate Buy" with an average 12-month price target of approximately $209 to $215, implying significant upside from current levels. Several firms adjusted their price targets upward in January ahead of the earnings release, reflecting confidence in a potential turnaround. TD Cowen raised its target to $251 from $197, while Citigroup increased its target to $265 from $200, both maintaining Buy ratings. Bank of America also upgraded the stock to Buy in December 2025, anticipating market normalization by 2026 and increased biopharmaceutical R&D spending.
The broader contract research organization (CRO) sector faces a complex landscape in 2026. While long-term structural drivers such as increasing R&D outsourcing and technological integration support growth prospects, the near-term environment remains challenging. Analysts point to macroeconomic volatility, regulatory shifts, and a looming patent cliff that could jeopardize over $300 billion in biopharmaceutical sales between 2026 and 2030 as factors that could impact R&D budgets.
From a technical perspective, Charles River's stock recently entered oversold territory, with the 14-day Relative Strength Index dropping below 30 in early February before recovering to approximately 39.8 by February 17. The stock fell below its 50-day moving average on February 4, signaling a shift to a downward trend that has since accelerated following the earnings announcement. Despite the recent weakness, institutional investors have maintained their positions, with approximately 98.9% of shares held by institutional owners.
For investors weighing Charles River Laboratories at current levels, the key question centers on the trajectory of biopharmaceutical demand and the company's ability to execute on its restructuring initiatives. The $225 million in annual cost savings expected by 2026 through operational restructuring and site consolidation should provide a margin cushion as the company navigates the demand environment. However, the flat revenue guidance suggests that significant top-line growth may remain elusive until later in the year, testing investor patience in the interim.